DOP2001000217A - Agente terapéutico cristalino - Google Patents

Agente terapéutico cristalino

Info

Publication number
DOP2001000217A
DOP2001000217A DO2001000217A DO2001000217A DOP2001000217A DO P2001000217 A DOP2001000217 A DO P2001000217A DO 2001000217 A DO2001000217 A DO 2001000217A DO 2001000217 A DO2001000217 A DO 2001000217A DO P2001000217 A DOP2001000217 A DO P2001000217A
Authority
DO
Dominican Republic
Prior art keywords
crystal
therapeutic agent
pyridylsulfoni
ethylpiperazine
polymorph
Prior art date
Application number
DO2001000217A
Other languages
English (en)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of DOP2001000217A publication Critical patent/DOP2001000217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Un polimorfo de 1-{6-etoxi-5-[3-etil-6,7-dihidro-2-(2-metoxietil)-7-oxo-2h-pirazolo[4,3-d]pirimidin-5-il]-3-piridilsulfoni}-4-etilpiperazina.
DO2001000217A 2000-07-28 2001-07-26 Agente terapéutico cristalino DOP2001000217A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
DOP2001000217A true DOP2001000217A (es) 2002-10-30

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000217A DOP2001000217A (es) 2000-07-28 2001-07-26 Agente terapéutico cristalino

Country Status (46)

Country Link
EP (1) EP1305314B1 (es)
JP (1) JP2004505087A (es)
KR (1) KR100457937B1 (es)
CN (1) CN1207297C (es)
AP (1) AP1400A (es)
AR (1) AR032628A1 (es)
AT (1) ATE286901T1 (es)
AU (2) AU7269001A (es)
BG (1) BG107266A (es)
BR (1) BR0112734A (es)
CA (1) CA2417264C (es)
CZ (1) CZ2003126A3 (es)
DE (1) DE60108398T2 (es)
DO (1) DOP2001000217A (es)
DZ (1) DZ3364A1 (es)
EA (1) EA004681B1 (es)
EC (1) ECSP034454A (es)
EE (1) EE200300045A (es)
ES (1) ES2231521T3 (es)
GE (1) GEP20053494B (es)
HK (1) HK1055954A1 (es)
HR (1) HRP20030061A2 (es)
HU (1) HUP0302982A3 (es)
IL (1) IL153226A0 (es)
IN (1) IN2002MU01649A (es)
IS (1) IS6626A (es)
MA (1) MA26931A1 (es)
MX (1) MX233602B (es)
MY (1) MY117831A (es)
NO (1) NO324220B1 (es)
NZ (1) NZ523226A (es)
OA (1) OA12337A (es)
PA (1) PA8523501A1 (es)
PE (1) PE20020277A1 (es)
PH (1) PH12001001922B1 (es)
PL (1) PL365133A1 (es)
PT (1) PT1305314E (es)
SK (1) SK572003A3 (es)
SV (1) SV2001000570A (es)
TN (1) TNSN01112A1 (es)
TW (1) TWI285643B (es)
UA (1) UA72631C2 (es)
UY (1) UY26854A1 (es)
WO (1) WO2002010171A1 (es)
YU (1) YU4703A (es)
ZA (1) ZA200301457B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
RS20050810A (en) 2003-04-29 2007-08-03 Pfizer Inc., 5,7-diaminopyrazolo(4,3-d)pyrimidines useful in the treatment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3721077B2 (ja) * 1998-04-20 2005-11-30 ファイザー・インク 性的不全を治療するためのピラゾロピリミジノンｃＧＭＰＰＤＥ５阻害剤
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
NO20030416D0 (no) 2003-01-27
ATE286901T1 (de) 2005-01-15
WO2002010171A1 (en) 2002-02-07
AP2001002234A0 (en) 2001-09-30
MX233602B (es) 2006-01-10
KR100457937B1 (ko) 2004-11-20
UY26854A1 (es) 2002-02-28
YU4703A (sh) 2006-01-16
BR0112734A (pt) 2004-08-10
CN1444585A (zh) 2003-09-24
DZ3364A1 (fr) 2002-02-07
DE60108398D1 (de) 2005-02-17
ZA200301457B (en) 2004-04-28
IL153226A0 (en) 2003-07-06
DE60108398T2 (de) 2005-12-22
EP1305314B1 (en) 2005-01-12
AR032628A1 (es) 2003-11-19
NO20030416L (no) 2003-02-05
GEP20053494B (en) 2005-04-25
MXPA03000856A (es) 2003-06-06
AU7269001A (en) 2002-02-13
ECSP034454A (es) 2003-03-10
TWI285643B (en) 2007-08-21
MY117831A (en) 2004-08-30
JP2004505087A (ja) 2004-02-19
IN2002MU01649A (es) 2004-12-11
HUP0302982A3 (en) 2005-01-28
EA200300079A1 (ru) 2003-06-26
CA2417264C (en) 2007-06-12
HRP20030061A2 (en) 2003-04-30
CN1207297C (zh) 2005-06-22
PT1305314E (pt) 2005-04-29
EA004681B1 (ru) 2004-06-24
SK572003A3 (en) 2004-05-04
CZ2003126A3 (cs) 2004-02-18
PH12001001922B1 (en) 2006-11-21
PL365133A1 (en) 2004-12-27
PA8523501A1 (es) 2002-10-24
TNSN01112A1 (fr) 2005-11-10
AP1400A (en) 2005-04-28
ES2231521T3 (es) 2005-05-16
PE20020277A1 (es) 2002-05-11
UA72631C2 (uk) 2005-03-15
EP1305314A1 (en) 2003-05-02
MA26931A1 (fr) 2004-12-20
HUP0302982A2 (hu) 2003-12-29
NZ523226A (en) 2003-07-25
EE200300045A (et) 2004-12-15
CA2417264A1 (en) 2002-02-07
KR20030016430A (ko) 2003-02-26
NO324220B1 (no) 2007-09-10
BG107266A (bg) 2003-07-31
OA12337A (en) 2006-05-15
AU2001272690B2 (en) 2005-12-08
SV2001000570A (es) 2002-09-03
HK1055954A1 (en) 2004-01-30
IS6626A (is) 2002-11-18

Similar Documents

Publication Publication Date Title
DE60236102D1 (en) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
MXPA04002537A (es) Alquinos como inhibidores de metaloproteinasa de matriz.
BR9609617B1 (pt) derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
EE200000320A (et) Uudsed ühendid
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
DE60112974D1 (en) Carbolinderivate
ATE231872T1 (de) Thiazolopyrimidinderivate
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
HRP20020198B1 (en) Moxifloxacin formulation containing common salt
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
DE60216233D1 (en) Carbolinderivate
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
MXPA03010761A (es) Combinaciones farmaceuticas.
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
EP1140900A4 (en) PYRAZOLE COMPOUNDS AND USE OF SUCH COMPOUNDS
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
DOP2001000217A (es) Agente terapéutico cristalino
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
IS4174A (is) Ný notkun á lyfjafræðilega viðurkenndu salti
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents